we aspire to be the patient-preferred biotech leader.
Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.
In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success.
Virtual fireside chat
In-person meetings in London
In-person meetings in San Francisco
Based on UCB’s current assessment of the COVID-19 pandemic, UCB remains confident in the fundamental underlying demand for its products and its prospects for long-term growth. UCB will continue to closely follow evolving COVID-19 pandemic diligently to assess potential near- and mid-term challenges.
The figures of the guidance 2023 and 2025 as mentioned below were calculated on the same basis as the actual figures for 2022.
More information closer to the date
€ 5.15 - 5.35 billion
based on expected launch contributions, the full annualized negative impact from the loss of exclusivity for VIMPAT® in the U.S. and Europe, and continued solid contribution from the existing product portfolio
2023 adj. EBITDA
22.5% - 23.5%
reflecting investments in the upcoming launches and the late-stage development pipeline, continued strong cost discipline and annualized inflation impact
2023 Core EPS
€ 3.40 - 3.80
based on an average of 190 million shares outstanding
at least € 6 billion
2025 adj. EBITDA
Low- to mid-thirties
2025 Improved ESG
Contact UCB IR Team
email@example.com or a specific team member:
- Antje Witte, Head of Investor Relations
Tel: +32 2 559 9414
- Sahar Yazdian, Investor Relations Lead
Tel: +32 2 559 9137
- Julien Bayet, Investor Relations Lead
Tel: +32 2 559 9580